Presentation is loading. Please wait.

Presentation is loading. Please wait.

Intermediate Risk TAVR 1 Year Later

Similar presentations


Presentation on theme: "Intermediate Risk TAVR 1 Year Later"— Presentation transcript:

1 Intermediate Risk TAVR 1 Year Later
Stephen Bailey, MD Director, Division of Cardiac Surgery Allegheny General Hospital September 27, 2017

2 Disclosure The information provided is the experience of the Allegheny General Hospital, and Edwards Lifesciences has not independently evaluated these data. Outcomes are dependent upon a number of facility and surgeon factors which are outside Edwards’ control. These data should not be considered promises or guarantees by Edwards that the outcomes presented here will be achieved by an individual facility. Stephen Bailey is a paid consultant to Edwards Lifesciences

3 AGH

4 Intermediate Risk One Year Later
What is the opinion of heart team to IR? Impact of RCT data What is the view of referring physicians? What is the view of patients? How has IR impacted our program? What % of IR patients have TAVR? How have we accommodated growth?

5 AGH TAVR Surgical clinic 3-4 new patients 3-4 mornings/ week
CT/ TTE 4-5 TAVR every Monday + 2 Fridays/month

6 AGH OHS Volume

7 AGH OHS Volume

8 TAVR Access

9 DRG Breakdown per Year

10 Trend of Average STS scores

11 Impact of Intermediate risk

12 Impact of Intermediate Risk on Length of Stay

13 TAVR Complications (In-Hospital)

14 TAVR Anesthesia

15 ICU Hours

16 Intermediate Risk One Year Later
What is the opinion of heart team to IR? Impact of RCT data What is the view of referring physicians? What is the view of patients? How has IR impacted our program? What % of IR patients have TAVR? How have we accommodated growth?

17 Summary Intermediate risk came during ongoing evolution of evaluation and treatment protocols Overall risk profile of our patients trending slowly down (never knew there were so many 90 year olds) Program/ pathway refinement dovetailed nicely with IR approval to enhance financial performance

18 Thank you

19 Please see important safety information at the speaker’s podium
Edwards and Edwards Lifesciences are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners. PP--US-2342 v1.0


Download ppt "Intermediate Risk TAVR 1 Year Later"

Similar presentations


Ads by Google